MorphoSys AG (MPSYY.PK) Tuesday reported fourth-quarter consolidated profit of 3.2 million euros, compared to a loss of 4.8 million euros in the same period last year.
Earnings before interest and taxes, or EBIT, totaled 4.4 million euros, compared to a loss of 8.0 million euros last year.
Fourth-quarter included a loss of 0.1 million euros from discontinued operations.
Group revenues increased to 16.5 million euros from 12.3 million euros last year.
Operating expenses dropped to 12.2 million euros from 20.4 million euros last year.
Revenues and costs arising from the AbD Serotec segment are classified as discontinued operations, due to the sale of segment to Bio-Rad.
For comments and feedback: editorial@rttnews.com